

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ





شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغييرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار





بعض الوثائق الأصلية تالفة





بالرسالة صفحات لم ترد بالأصل





Evaluation of the Effect of Combination Chemotherapy with Five-Day Infusion of Fluorouracil Plus Vinorelbine in Pretreated Metastatic Breast Cancer Patients

Thesis

*Submitted for Partial Fulfillment of Master Degree
in Clinical Oncology and Nuclear Medicine*

By

Rasha Salah El-din Mohammed

M.B.B.CH.

Faculty of Medicine – Minya University

Supervised by

Prof. Dr. Tarek Hussein Kamel

*Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Ass. Prof. Dr. Mai Mohamed Ali Ezz El Din

*Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Dr. Ahmed Aly Nagy

*Lecturer of Clinical Oncology and Nuclear Medicine
Faculty of Medicine, Ain Shams University*

Faculty of Medicine, Ain Shams University

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

قَالَ

لَسْبِحَانَكَ لَا مَعْلَمَ لَنَا
إِلَّا مَا مَعْلَمْتَنَا إِنَّكَ أَنْتَ
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr. Tarek Hussein Kamel**, Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Ass. Prof. Dr. Mai Mohamed Ali Ezz El Din**, Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her sincere efforts, fruitful encouragement, valuable instructions and kind help .*

*I am deeply thankful to **Dr. Ahmed Aly Nagy**, Lecturer of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance all are within amazing respect of time and great ethics from which I learned .*

*Special thanks are due to my great professors and colleagues in El Salam Oncology Centre, **Prof. Dr. Rasha Fahmi**, Clinical Oncology Consultant and Director of El Salam Oncology Centre, for her administrative and personal support. **Dr. Amir Elsaeed**, Assistant Director of El Salam Oncology Centre, for his wise guidance and help. **Dr. Ahmed Essam**, Resident Oncologist at El Salam Oncology Centre, for his inspirational scientific ideas.*

*I would like to express my hearty thanks to all my family and **friends** especially **my great mother, brother and soul of my father** for their support till this work was completed with special thanks to **my patients**.*

Rasha Salah El-din Mohammed

List of Contents

Title	Page No.
List of Tables.....	6
List of Figures	8
List of Abbreviations.....	11
Chapter 1: Introduction.....	13
▪ Epidemiology	13
▪ Risk Factors	14
▪ Pathology of breast cancer	26
○ Other Histologic Types	38
○ Prognostic and predictive factors in pathology of metastatic breast cancer	42
▪ Diagnosis.....	48
Chapter 2: Treatment in Metastatic Breast Cancer	61
▪ Goals of treatment in the metastatic breast cancer.....	61
▪ Selecting the strategy of treatment of metastatic breast cancer	63
○ Tumor biology.....	63
○ Prediction of response	64
○ Endocrine therapy (alone or in combination with targeted agents) versus chemotherapy:	65
▪ Selecting chemotherapy in metastatic breast cancer	69
○ Indication.....	69
○ Factors Influencing Chemotherapy Choice:.....	69
○ Sequential single agents versus combination chemotherapy	75
▪ Combination of fluorouracil and vinorelbine	76
○ Pharmacology of Fluorouracil(5-FU).....	77
○ Pharmacology of Vinorelbine(Navelbine).....	79
○ Studies evaluated the effect of combination 5-days C.I. of Fluorouracil plus Vinorelbine in metastatic breast cancer	81

List of Contents *cont...*

Title	Page No.
Aim of the Work	88
Patients and Methods	89
Results	94
Discussion	118
Summary	131
References	133
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table 1:	Incidence of subtypes of invasive and insitu nreast neoplasms	26
Table 2:	Comparative features of DCIS and LCIS.....	28
Table 3:	Classification systems for ductal carcinoma in situ.....	31
Table 4:	Previous studies evaluated combination of C.I. 5-FU and vinorelbine in metastatic breast cancer	87
Table 5:	Showing Age distribution in the study	95
Table 6:	Patient's characteristics illustrated in both frequency and percentage.....	99
Table 7:	Treatment's characteristics showing Nav/5Fu both line's number and cycles number	101
Table 8:	Showing adverse events with its grade and cycle of developing.....	103
Table 9:	Showing Objective Response of all patients.....	104
Table 10:	Showing Clinical Benefit Rate (CBR) achieved in the sudy.....	104
Table 11:	Showing correlations between CBR and patients characteristics.....	106
Table 12:	Showing Mean and Median of PFS.	107
Table 13:	Showing correlations between patients characteristics and FFS.....	108

List of Tables cont...

Table No.	Title	Page No.
Table 14:	Showing occurrence of event of death in the study.	111
Table 15:	Showing mean and median OS estimated in the study.....	112
Table 16:	Showing correlations between patients characteristics and OS.....	113
Table 17:	Multivariate analysis for Progression-free survival including the studied variables.....	116
Table 18:	Multivariate analysis for Overall survival including the studied variables	117

List of Figures

Fig. No.	Title	Page No.
Figure 1:	Comedo DCIS under light microscope	30
Figure 2:	Cribriform ductal carcinoma in situ under Light microscope.....	30
Figure 3:	Micropapillary ductal carcinoma in situ under light microscope	31
Figure 4:	Grade I infiltrating ductal carcinoma of the breast with (Panel A) of Low power view	34
Figure 5:	Grade II infiltrating carcinoma of the breast with (Panel A) of Low power view	34
Figure 6:	Grade III infiltrating ductal carcinoma of the breast with (Panel A) of Low power view	35
Figure 7:	Infiltrating lobular carcinoma of the breast with (Panel A) of Low power view	36
Figure 8:	Tubular carcinoma of the breast with (Panel A) of Low-power view and (Panel B) of High-power view demonstrates that the tubules are composed of columnar cells with relatively uniform nuclei	41
Figure 9:	Mucinous carcinoma of the breast with (Panel A) of Low power view and (Panel B) of High power view demonstrates that the nests are composed of cells with relatively uniform, low grade nuclei.....	41
Figure 10:	Medullary carcinoma of the breast with (Panel A) of Low power view of a medullary breast carcinoma and (Panel B) of High power view demonstrates that the tumor cells grow in a syncytial pattern and have marked nuclear atypia.	42
Figure 11:	Spot magnification view of a mammogram showing two small adjacent interconnected spiculated masses (red arrows).....	53

List of Figures *cont...*

Fig. No.	Title	Page No.
Figure 12:	Magnified craniocaudal mammogram showing linear branching calcifications in a segmental distribution (red arrow).....	53
Figure 13:	Showing frequency and percentage of performance status.....	94
Figure 14:	Showing Age distribution in the study.....	95
Figure 15:	Showing percentage of Presence of Family history in the study	96
Figure 16:	Showing percentage of patients with positive Family history of breast cancer in the study.	96
Figure 17:	Showing percentage of Menopausal status in the study.....	97
Figure 18:	Showing percentage of molecular subtypes in the study.....	97
Figure 19:	Showing frequency & percentage of site of mets in the study.....	98
Figure 20:	Showing percentage of Nav/5Fu line's number.....	100
Figure 21:	Showing percentage of Nav/5Fu cycles number.....	101
Figure 22:	Showing frequency & percentage of Toxicity/adverse events of Nav/5Fu.....	102
Figure 23:	Showing frequency & percentage of both objective response and CBR.....	105
Figure 24:	Showing Progression Free Survival estimated in the study.....	107
Figure 25:	Showing correlation between Age (</>46.5 yrs) and PFS.....	109
Figure 26:	Showing correlation between Menstrual status (pre/post) and PFS.....	109

List of Figures cont...

Fig. No.	Title	Page No.
Figure 27:	Showing correlation between TND molecular subtype Vs other molecular subtypes and PFS.....	110
Figure 28:	Showing correlation between Visceral Metastasis and PFS.	110
Figure 29:	Showing correlation between receiving Nav/5Fu as 2 nd line and PFS.....	111
Figure 30:	Showing Overall Survival estimated in the study.....	112
Figure 31:	Showing correlation between Age (</>46.5 yrs) and OS.	113
Figure 32:	Showing correlation between menstrual status (pre/post) and OS.....	114
Figure 33:	Showing correlation between TND molecular subtype Vs other molecular subtypes and OS.....	114
Figure 34:	Showing correlation between Visceral Metastasis and OS.	115
Figure 35:	Showing correlation between receiving Nav/5Fu as 2 nd line and OS.	115